Asia-Pacific region - Cost-effectiveness prevention and management of gastrointestinal and liver disease - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title Asia-Pacific region - Cost-effectiveness prevention and management of gastrointestinal and liver disease, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : Asia-Pacific region - Cost-effectiveness prevention and management of gastrointestinal and liver disease
link : Asia-Pacific region - Cost-effectiveness prevention and management of gastrointestinal and liver disease

Asia-Pacific region - Cost-effectiveness prevention and management of gastrointestinal and liver disease

Review Article
COST-EFFECTIVE OPTIONS FOR THE PREVENTION AND MANAGEMENT OF GASTROINTESTINAL AND LIVER DISEASE IN THE ASIA-PACIFIC REGION
Authors Ian C Roberts-Thomson, Thomas Lung
Accepted manuscript online: 17 August 2017
Full publication history DOI: 10.1111/jgh.13925 

Download Full Text Article

Abstract
The Asia-Pacific region contains more than half of the world's population and is markedly heterogeneous in relation to income levels and the provision of public and private health services. For low-income countries, the major health priorities are child and maternal health. In contrast, priorities for high-income countries include vascular disease, cancer, diabetes, dementia and mental health disorders as well as chronic inflammatory disorders such as hepatitis B and hepatitis C. Cost-effectiveness analyses are methods for assessing the gains in health relative to the costs of different health interventions. Methods for measuring health outcomes include years of life saved [or lost], quality-adjusted life years [QALYs] and disability-adjusted life years [DALYs]. The incremental cost-effectiveness ratio [ICER] measures the cost [usually in US dollars] per life year saved, QALY gained or DALY averted of one intervention relative to another. In low-income countries, approximately 50% of infant deaths [<5years] are caused by gastroenteritis, the major pathogen being rotavirus infection. Rotavirus vaccines appear to be cost-effective but, thus far, have not been widely adopted. In contrast, infant vaccination for hepatitis B is promoted in most countries with a striking reduction in the prevalence of infection in vaccinated individuals. Cost-effectiveness analyses have also been applied to newer and more expensive drugs for hepatitis B and C and to government-sponsored programs for the early detection of hepatocellular, gastric and colorectal cancer. Most of these studies reveal that newer drugs and surveillance programs for cancer are only marginally cost-effective in the setting of a high-income country.

Source - Journal of Gastroenterology and Hepatology

Thus articles Asia-Pacific region - Cost-effectiveness prevention and management of gastrointestinal and liver disease

that is all articles Asia-Pacific region - Cost-effectiveness prevention and management of gastrointestinal and liver disease This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article Asia-Pacific region - Cost-effectiveness prevention and management of gastrointestinal and liver disease the link address https://newsaninpiration.blogspot.com/2017/08/asia-pacific-region-cost-effectiveness.html

Tweet

Subscribe to receive free email updates: